Valuation: Algorae Pharmaceuticals Limited

Market Cap 1.82Cr 1.3Cr 1.13Cr 1.07Cr 96.99L 1.82Cr 124.48Cr 13Cr 4.94Cr 63Cr 4.87Cr 4.76Cr 203.63Cr P/E 2025
-10x
P/E 2026 -6.55x
Enterprise Value 1.43Cr 1.02Cr 88.71L 83.76L 76.06L 1.43Cr 98Cr 10Cr 3.87Cr 50Cr 3.82Cr 3.74Cr 159.69Cr EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
66.95%
Yield 2025 *
-
Yield 2026 -
1 week-10.00%
Current month-10.00%
1 month-10.00%
3 months-14.29%
6 months-40.00%
Current year-35.71%
1 week 0.01
Extreme 0.009
0.01
1 month 0.01
Extreme 0.009
0.01
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.008
0.02
3 years 0
Extreme 0.005
0.02
5 years 0
Extreme 0.003999
0.02
10 years 0
Extreme 0.003999
0.28
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 19/06/2023
Corporate Secretary - 01/07/2026
Corporate Secretary - 01/07/2026
Director TitleAgeSince
Chairman 52 05/01/2023
Director/Board Member - 10/03/2026
Director/Board Member 52 14/07/2026
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-10.00%+20.00%-35.71% 1.3Cr
-0.31%+5.79%+47.13%+99.00% 7.09TCr
+0.39%+2.06%+39.38%+78.27% 6.25TCr
+0.50%+7.13%+33.27%+16.01% 2.63TCr
-3.21%-7.27%-17.10%+356.10% 2.62TCr
-2.64%-0.69%-0.17%-13.01% 2.41TCr
+0.71%+8.03%+25.03%-12.74% 2.07TCr
+2.12%-5.86%+161.58%+329.34% 1.54TCr
-0.22%+3.99%+45.54%+172.46% 1.45TCr
+0.73%+1.71%-5.51%+849.47% 1.42TCr
Average -0.19%+0.57%+34.92%+183.92% 2.75TCr
Weighted average by Cap. -0.28%+1.49%+35.68%+148.21%

Financials

2025 2026
Net sales - -
Net income -8L -6L -5L -5L -4L -8L -5.48Cr -56.3L -21.73L -2.78Cr -21.44L -20.97L -8.96Cr -27.11L -19.27L -16.8L -15.87L -14.41L -26.99L -18Cr -1.9Cr -73.34L -9.4Cr -72.39L -70.78L -30Cr
Net Debt -23.19L -16.49L -14.38L -13.57L -12.33L -23.1L -16Cr -1.63Cr -62.75L -8.04Cr -61.93L -60.56L -26Cr -39.37L -27.99L -24.41L -23.05L -20.93L -39.21L -27Cr -2.76Cr -1.07Cr -14Cr -1.05Cr -1.03Cr -44Cr
Logo Algorae Pharmaceuticals Limited
Algorae Pharmaceuticals Limited is an Australia-based artificial-intelligence (AI) enabled pharmaceutical development company. The Company’s proprietary AI platform, Algorae Operating System (AlgoraeOS), is an AI platform that leverages extensive medical and scientific databases from various disciplines within an advanced system at the intersection of AI and pharmaceutical research. Its other drug candidates include AI-116, AI-168, NTCELL. AI-116 is a combination drug candidate made up of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. It is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease. AI-168 is a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient, which is conceptualized to be a potential treatment for cardiovascular disease, including hypertension. NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells.
Employees
48
Date Price Change Volume
18/26/18 A$0.009000 0.00% 1,68,855
17/26/17 A$0.009000 0.00% 3,63,351
16/26/16 A$0.009000 0.00% 17,38,327
15/26/15 A$0.009000 -10.00% 14,47,580
11/26/11 A$0.0100 +11.11% 23,201
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!